The Location of Missense Variants in the Human GIP Gene Is Indicative for Natural Selection

The intestinal hormone, glucose-dependent insulinotropic polypeptide (GIP), is involved in important physiological functions, including postprandial blood glucose homeostasis, bone remodeling, and lipid metabolism. While mutations leading to physiological changes can be identified in large-scale seq...

Full description

Bibliographic Details
Published in:	Frontiers in Endocrinology
Main Authors:	Peter Lindquist, Lærke Smidt Gasbjerg, Jacek Mokrosinski, Jens Juul Holst, Alexander Sebastian Hauser, Mette Marie Rosenkilde
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-06-01
Subjects:	GIP - glucose-dependent insulinotropic peptide missense variants pharmacogenomics GIPR GPCR (G protein coupled receptor) UK Biobank
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2022.891586/full

Similar Items

The evolution of the therapeutic concept ‘GIP receptor antagonism’
by: Frederikke Koefoed-Hansen, et al.
Published: (2025-05-01)

Editorial: The impact of GIP/GIPR on metabolic diseases: how the field is evolving
by: Kirk Habegger, et al.
Published: (2025-10-01)

Physiology and clinical applications of GIP
by: Shunsuke Yamane, et al.
Published: (2025-07-01)

Loss of GIPR in LEPR cells impairs glucose control by GIP and GIP:GLP-1 co-agonism without affecting body weight and food intake in mice
by: Seun Akindehin, et al.
Published: (2024-05-01)

The performance of AlphaMissense to identify genes influencing disease
by: Yiheng Chen, et al.
Published: (2024-10-01)

The role of GIPR in food intake control
by: Paula-Peace James-Okoro, et al.
Published: (2025-03-01)

Tirzepatide, GIP(1-42) and GIP(1-30) display unique signaling profiles at two common GIP receptor variants, E354 and Q354
by: Tayla A. Rees, et al.
Published: (2024-10-01)

The agony and the efficacy: central mechanisms of GLP-1 induced adverse events and their mitigation by GIP
by: Jonathan D. Douros, et al.
Published: (2025-02-01)

Incretin Hormones and Type 2 Diabetes—Mechanistic Insights and Therapeutic Approaches
by: Geke Aline Boer, et al.
Published: (2020-12-01)

Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems
by: Bin Yang, et al.
Published: (2022-12-01)

Imaging of the Glucose-Dependent Insulinotropic Polypeptide Receptor Using a Novel Radiolabeled Peptide Rationally Designed Based on Endogenous GIP and Synthetic Exendin-4 Sequences
by: Irina Velikyan, et al.
Published: (2022-12-01)

Glucose-dependent insulinotropic polypeptide (GIP)
by: Timo D. Müller, et al.
Published: (2025-05-01)

Evidence for Involvement of GIP and GLP-1 Receptors and the Gut-Gonadal Axis in Regulating Female Reproductive Function in Mice
by: Dawood Khan, et al.
Published: (2022-11-01)

What combines best with GLP-1 for obesity treatment: GIP receptor agonists or antagonists?
by: Jens Juul Holst
Published: (2021-05-01)

Chronic GIPR agonism results in pancreatic islet GIPR functional desensitisation
by: Iona Davies, et al.
Published: (2025-02-01)

GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight loss in preclinical mouse model for cardio-metabolic disease
by: Stephan Sachs, et al.
Published: (2023-08-01)

Glucose-Dependent Insulinotropic Polypeptide Plasma Level Influences the Effect of n-3 PUFA Supplementation
by: Joanna Goralska, et al.
Published: (2022-08-01)

Functional and Structural Impact of Deleterious Missense Single Nucleotide Polymorphisms in the NR3C1, CYP3A5, and TNF-α Genes: An In Silico Analysis
by: Navakanth Raju Ramayanam, et al.
Published: (2022-09-01)

Contribution of GIP and GLP-1 to the Insulin Response to Oral Administration of Glucose in Female Mice
by: Bo Ahrén
Published: (2023-02-01)

Benchmarking computational variant effect predictors by their ability to infer human traits
by: Daniel R. Tabet, et al.
Published: (2024-07-01)

Association of MTHFR missense variants with thromboembolic diseases and coagulation factor levels in European populations
by: Iyas Daghlas, et al.
Published: (2025-04-01)

AT-7687, a novel GIPR peptide antagonist, combined with a GLP-1 agonist, leads to enhanced weight loss and metabolic improvements in cynomolgus monkeys
by: Mette H. Jensen, et al.
Published: (2024-10-01)

Secretion of glucagon, GLP-1 and GIP may be affected by circadian rhythm in healthy males
by: Dorte B. Zilstorff, et al.
Published: (2024-03-01)

Common variants in the hERG (KCNH2) voltage-gated potassium channel are associated with altered fasting and glucose-stimulated plasma incretin and glucagon responses
by: Line Engelbrechtsen, et al.
Published: (2018-03-01)

Role of a Dual Glucose-Dependent Insulinotropic Peptide (GIP)/Glucagon-like Peptide-1 Receptor Agonist (Twincretin) in Glycemic Control: From Pathophysiology to Treatment
by: Maria Chiara Pelle, et al.
Published: (2021-12-01)

Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
by: Patrick J. Knerr, et al.
Published: (2022-09-01)

GIP1 and GIP2 Contribute to the Maintenance of Genome Stability at the Nuclear Periphery
by: Gaurav Singh, et al.
Published: (2022-01-01)

Stimulating intestinal GIP release reduces food intake and body weight in mice
by: Jo E. Lewis, et al.
Published: (2024-06-01)

Plasma metabolomic profiles of dementia: a prospective study of 110,655 participants in the UK Biobank
by: Xinyu Zhang, et al.
Published: (2022-08-01)

Effect of GIP and GLP-1 infusion on bone resorption in glucose intolerant, pancreatic insufficient cystic fibrosis
by: Wang Shin Lei, et al.
Published: (2025-06-01)

Noninvasive Evaluation of GIP Effects on β-Cell Mass Under High-Fat Diet
by: Sakura Kiyobayashi, et al.
Published: (2022-07-01)

Incretin-Based Multi-Agonist Peptides Are Neuroprotective and Anti-Inflammatory in Cellular Models of Neurodegeneration
by: Katherine O. Kopp, et al.
Published: (2024-07-01)

Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
by: Qiyuan Keith Liu
Published: (2024-07-01)

Glucose-dependent insulinotropic peptide receptor overexpression in adrenocortical hyperplasia in MEN1 syndrome without loss of heterozygosity at the 11q13 locus
by: Marcia Helena Soares Costa, et al.
Published: (2011-01-01)

The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction
by: Rizvi AA, et al.
Published: (2022-04-01)

Dysglycemia Shapes Visceral Adipose Tissue’s Response to GIP, GLP-1 and Glucagon in Individuals with Obesity
by: Tiago Morais, et al.
Published: (2023-04-01)

Maturity‐Onset Diabetes of the Young (MODY) With HNF1B p.Glu105Lys Mutation Achieving Significant Insulin Reduction on Tirzepatide: A Case Report
by: Mihiro Sue, et al.
Published: (2025-02-01)

Increased risk of hospitalization for various disorders after COVID-19 infection: A Cohort study of the UK biobank spanning over a hundred disease categories
by: Yong Xiang, et al.
Published: (2025-06-01)

Circulating metabolic biomarkers predict incident sepsis: a large-scale population study in the UK Biobank
by: Hao Bai, et al.
Published: (2025-08-01)

Identification of Associations with Dermatologic Diseases through a Focused GWAS of the UK Biobank
by: Jason C. Klein, et al.
Published: (2025-01-01)